Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatmentVanessa Neiens, Marina Pavlidou, Cornelia Wurzenberger et al.|Nature Communications|2025Cited by 13
Development of PRS-220, a potential best-in-class, inhaled CTGF/CCN2 inhibitor for the treatment of IPFVanessa Welk, Shane A. Olwill, Eva-Maria Hansbauer et al.|Unknown|2021Cited by 3